HIV/AIDS合并结核分枝杆菌感染者抗结核治疗前后红细胞系统变化情况分析
Analysis of Changes in Erythrocyte System before and after Anti-Tuberculosis Treatment in HIV/AIDS Patients with Mycobacterium tuberculosis Infection
DOI: 10.12677/md.2026.161023, PDF,    科研立项经费支持
作者: 谢 祺, 杨海花, 李健健, 张玉迎, 樊红丽*：云南省传染病医院检验科，云南 昆明；昆明医科大学附属传染病医院检验科，云南 昆明；周 高：昆明医科大学公共卫生学院，云南 昆明
关键词: HIV/MTB合并感染者；HIV；贫血；抗结核治疗；红细胞系统；HIV/MTB Co-Infected Patients； HIV； Anemia； Anti-Tuberculosis Treatment； Erythrocyte System
摘要: 目的：探讨艾滋病病毒(Human Immunodeficiency Virus, HIV)合并结核分枝杆菌(Mycobacterium tuberculosis, MTB)感染者的贫血特点及抗结核治疗前后红细胞系统变化情况，为临床治疗提供理论依据。方法：回顾性分析2019~2023年某医院收治的58例HIV/MTB合并感染者(A组)及82例HIV单一感染者(B组)的红细胞系检测结果，采用SPSS 27.0软件进行统计分析。结果：A组在抗结核治疗前基线(0周)及治疗以后不同时期(1周、2周、4周、8周、12周、24周)与B组在抗反转录治疗(Anti-Retroviral Therapy, ART)前基线(0周)的红细胞系检测指标：红细胞(RBC)、血红蛋白(HGB)、红细胞压积(HCT)、平均红细胞体积(MCV)、红细胞分布宽度变异系数(RDW-CV)比较结果显示：B组基线RBC、HGB、HCT均较A组基线高(P均 < 0.05)，但MCV、RDW-CV无显著差异(P均 > 0.05)；两组患者均以正细胞性贫血为主，差异无统计学意义(P > 0.05)；A组在接受抗结核药物治疗4周、8周、12周、24周时RBC、HGB、HCT、MCV均高于基线，差异均有统计学意义(P均 < 0.05)；在接受抗结核治疗2周时RDW-CV高于基线(P < 0.05)；但其他时间点差异均无统计学意义(P均 > 0.05)。结论：未经抗结核治疗的HIV/MTB合并感染者较HIV单一感染者更易出现贫血；经4周的抗结核治疗后，有助于改善HIV/MTB合并感染患者的贫血状况。
Abstract: Objective: To explore the characteristics of anemia in patients co-infected with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (MTB), and the changes in the erythrocyte system before and after anti-tuberculosis treatment, in order to provide a theoretical basis for clinical treatment. Methods: A retrospective analysis was conducted on the erythrocyte system test results of 58 patients with HIV/MTB co-infection (Group A) and 82 patients with HIV mono-infection (Group B) admitted to a hospital from 2019 to 2023, using SPSS 27.0 software for statistical analysis. Results: Comparisons of erythrocyte system test indicators including Red Blood Cells (RBC), Hemoglobin (HGB), Hematocrit (HCT), Mean Corpuscular Volume (MCV), and Red Cell Distribution Width CV (RDW-CV) at baseline (0 weeks) before anti-tuberculosis treatment and at different periods after treatment (1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks) in Group A, and at baseline (0 weeks) before HARRT treatment in Group B, showed that the baseline RBC, HGB, and HCT in Group B were higher than those in Group A (P < 0.05 for all), but there was no significant difference in MCV and RDW-CV (P > 0.05 for both); the type of anemia in both groups was mainly normocytic anemia, with no statistically significant difference (P > 0.05); in Group A, RBC, HGB, HCT, and MCV were all higher than baseline at 4 weeks, 8 weeks, 12 weeks, and 24 weeks after anti-tuberculosis treatment, with statistically significant differences (P < 0.05 for all); RDW-CV was higher than baseline at 2 weeks after anti-tuberculosis treatment (P < 0.05); but there were no statistically significant differences at other time points (P > 0.05). Conclusion: Patients with HIV/MTB co-infection without anti-tuberculosis treatment are more prone to anemia than those with HIV mono-infection; anti-tuberculosis treatment for 4 weeks helps to improve the anemic condition of patients with HIV/MTB co-infection.
文章引用：谢祺, 杨海花, 李健健, 张玉迎, 周高, 樊红丽. HIV/AIDS合并结核分枝杆菌感染者抗结核治疗前后红细胞系统变化情况分析[J]. 医学诊断, 2026, 16(1): 165-172. https://doi.org/10.12677/md.2026.161023

参考文献

[1] WHO (2025) Global Tuberculosis Report.
[2] Ageru, T.A., Koyra, M.M., Gidebo, K.D. and Abiso, T.L. (2019) Anemia and Its Associated Factors among Adult People Living with Human Immunodeficiency Virus at Wolaita Sodo University Teaching Referral Hospital. PLOS ONE, 14, e0221853. [Google Scholar] [CrossRef] 
[3] Huibers, M.H.W., Bates, I., McKew, S., Allain, T.J., Coupland, S.E., Phiri, C., et al. (2020) Severe Anaemia Complicating HIV in Malawi; Multiple Co-Existing Aetiologies Are Associated with High Mortality. PLOS ONE, 15, e0218695. [Google Scholar] [CrossRef] 
[4] Ezeamama, A.E., Sikorskii, A., Bajwa, R.K., Tuke, R., Kyeyune, R.B., Fenton, J.I., et al. (2019) Evolution of Anemia Types during Antiretroviral Therapy—Implications for Treatment Outcomes and Quality of Life among HIV-Infected Adults. Nutrients, 11, E755. [Google Scholar] [CrossRef] 
[5] 肺结核诊断WS 288-2017 [J]. 中国感染控制杂志, 2018, 17(7): 642-652.
[6] Zenebe, W.A., Anbese, A.T. and Tesfaye, T.S. (2019) Anemia and Associated Factors among Adult People Living with HIV/AIDS Receiving Anti-Retroviral Therapy at Gedeo Zone, SNNPR, Ethiopia, 2018. HIV/AIDS—Research and Palliative Care, 11, 351-356. [Google Scholar] [CrossRef] 
[7] Fekene, T.E., Juhar, L.H., Mengesha, C.H. and Worku, D.K. (2018) Prevalence of Cytopenias in both HAART and HAART Naïve HIV Infected Adult Patients in Ethiopia: A Cross Sectional Study. BMC Hematology, 18, Article No. 8. [Google Scholar] [CrossRef] 
[8] Ghosh, K., Shome, D.K., Kulkarni, B., Ghosh, M.K. and Ghosh, K. (2023) Fibrosis and Bone Marrow: Understanding Causation and Pathobiology. Journal of Translational Medicine, 21, Article No. 703. [Google Scholar] [CrossRef] 
[9] Brastianos, P.K., Swanson, J.W., Torbenson, M., Sperati, J. and Kara-kousis, P.C. (2006) Tuberculosis-Associated Haemophagocytic Syndrome. The Lancet Infectious Diseases, 6, 447-454. [Google Scholar] [CrossRef] 
[10] Deressa, T., Damtie, D., Workineh, M., et al. (2018) Anemia and Thrombocytopenia in the Cohort of HIV-Infected Adults in Northwest Ethiopia: A Facility-Based Cross-Sectional Study. EJIFCC, 29, 36-47.
[11] 邓岚兰, 杨新婷, 贾俊楠, 等. 2012-2016年北京市胸科医院肺结核合并症患者的回顾性分析[J]. 疾病监测, 2018, 33(4): 320-323.
[12] Weiss, G. and Goodnough, L.T. (2005) Anemia of Chronic Disease. New England Journal of Medicine, 352, 1011-1023. [Google Scholar] [CrossRef] 
[13] Noor, R.A., Abioye, A.I., Hertzmark, E., Darling, A.M., Aboud, S., Mugusi, F.M., et al. (2020) Impaired Hematological Status Increases the Risk of Mortality among HIV-Infected Adults Initiating An-tiretroviral Therapy in Tanzania. The Journal of Nutrition, 150, 2375-2382. [Google Scholar] [CrossRef] 
[14] Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., et al. (2019) Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological Studies (Second Edition). European Journal of Immunology, 49, 1457-1973. [Google Scholar] [CrossRef] 
[15] Harding, B.N., Whitney, B.M., Nance, R.M., Ruderman, S.A., Crane, H.M., Burkholder, G., et al. (2020) Anemia Risk Factors among People Living with HIV across the United States in the Current Treatment Era: A Clinical Cohort Study. BMC Infectious Diseases, 20, Article No. 238. [Google Scholar] [CrossRef] 
[16] Tamir, Z., Alemu, J. and Tsegaye, A. (2018) Anemia among HIV In-fected Individuals Taking ART with and without Zidovudine at Addis Ababa, Ethiopia. Ethiopian Journal of Health Sciences, 28, 73-82. [Google Scholar] [CrossRef] 
[17] 舒远路, 杨翠先, 张米等. HIV/AIDS-TB患者抗结核药物治疗强化期红细胞系的变化[J]. 中国感染控制杂志, 2019, 18(5): 396-402.
[18] Kutiyal, A.S. (2017) A Study of Haematological and Hae-mostasis Parameters and Hypercoagulable State in Tuberculosis Patients in Northern India and the Outcome with An-ti-Tubercular Therapy. Journal of Clinical and Diagnostic Research, 11, OC09-OC13. [Google Scholar] [CrossRef] 
[19] Kassa, E., Enawgaw, B., Gelaw, A. and Gelaw, B. (2016) Effect of Anti-Tuberculosis Drugs on Hematological Profiles of Tuberculosis Patients Attending at University of Gondar Hospital, Northwest Ethiopia. BMC Hematology, 16, Article No. 1. [Google Scholar] [CrossRef] 
[20] 王倩, 陈津红, 韩琴, 等. 441例抗结核药引起血液系统不良反应文献分析[J]. 中国药房, 2008, 19(5): 376-377.
[21] Shaw, J.B. and Wynn-Williams, N. (1954) Infectivity of Pulmonary Tuberculosis in Relation to Sputum Status. American Review of Tuberculo-sis, 69, 724-732.